Table 1.
Sequences of peptides derived from HR1 and HR2 regions of SARS-CoV spike proteina
| Peptideb | Residues |
|---|---|
| HR1-1(889–926) | NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA |
| HR1-2(909–948) | FNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQL |
| HR1-3(940–978) | ALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRL |
| HR1-4(975–1010) | IDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATK |
| HR1-5(989–1028) | YVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKG |
| HR2-1(1119–1159) | VYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV |
| HR2-2(1124–1162) | QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ |
| HR2-3(1129–1170) | SFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNE |
| HR2-4(1134–1173) | LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAK |
| HR2-5(1138–1178) | FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES |
| HR2-6(1144–1183) | PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQ |
| HR2-7(1149–1188) | GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY |
| HR2-8(1151–1196) | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW |
| HR2-9(1151–1187) | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK |
| HR2-10(1151–1185) | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL |
| HR2-11(1153–1187) | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK |
| HR2-12(1154–1196) | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW |
| HR2-13(1154–1192) | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI |
| HR2-14(1154–1187) | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK |
| HR2-15(1154–1182) | INASVVNIQKEIDRLNEVAKNLNESLIDL |
| HR2-16(1158–1196) | VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW |
| HR2-17(1158–1187) | VVNIQKEIDRLNEVAKNLNESLIDLQELGK |
| HR2-18(1161–1187) | IQKEIDRLNEVAKNLNESLIDLQELGK |
| HR2-19(1161–1196) | IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW |
| HR2-20(1165–1196) | IDRLNEVAKNLNESLIDLQELGKYEQYIKWPW |
a
The residues in bold are the peptides that show inhibition activity.
b
Numbers in the brackets are the beginning and end residues for each peptide corresponding to the spike protein.